Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Empagliflozin improves glycemic control in type 1 diabetes patients
Última actualización 18 de julio de 2026
Key finding
Hemoglobin A1C decreased by -0.18% (95% CI: -0.37, 0.005, P =0.009)
This study evaluated the effects of empagliflozin as an adjunct to insulin in patients with type 1 diabetes, showing significant reductions in blood sugar levels and insulin doses.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of empagliflozin as an adjunct to insulin in patients with type 1 diabetes, showing significant reductions in blood sugar levels and insulin doses.
Clinical relevance
These findings are significant as they suggest that empagliflozin can enhance diabetes management in patients with type 1 diabetes, potentially leading to better glycemic control and reduced insulin requirements. This could improve patients' quality of life and reduce the risk of diabetes-related complications.
Keep in mind
Limited generalizability due to specific population characteristics Short duration of the study may not capture long-term effects Potential for unmeasured confounders affecting outcomes
Published in
Referencia de la Revista
Publication details and source links for this paper.
Mostafa N, Farzad N, Alireza O, et al. Empagliflozin as an Adjunct to Insulin in Patients with Type 1 Diabetes: A Randomized Clinical Trial. Health Promotion Perspectives. 2024;14(4):380-387. doi:10.34172/hpp.42486
Efectos Principales
Hemoglobin A1C decreased by -0.18% (P = 0.009)
Fasting blood sugar decreased by -2.60 mg/dL (P = 0.035)
Total daily insulin dose decreased by -7.6 units (P = 0.003)
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Empagliflozin and BMI, Fasting blood sugar (FBS), Glucose iAUC (OGTT), and 2 more.
This study contributes evidence to
Primary intervention
Empagliflozin
Primary outcomes
- BMI
- Fasting blood sugar (FBS)
- Glucose iAUC (OGTT)
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
5
Related topics
5
Evidence pairs
902
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
SGLT2 Inhibitors and Fasting Glucose
Evidencia relacionada
Relación de evidencia
SGLT2 Inhibitors and Body Mass Index
Guardar evidencia
Relación de evidencia
SGLT2 Inhibitors and Postprandial and OGTT Glucose
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Fasting blood sugar (FBS)
Empagliflozin → Fasting blood sugar (FBS)
Empagliflozin → Fasting blood sugar (FBS)
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerReduction in Hemoglobin A1C levels
Empagliflozin → Reduction in Hemoglobin A1C levels
Empagliflozin → Reduction in Hemoglobin A1C levels
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerTotal daily insulin dose
Empagliflozin → Total daily insulin dose
Empagliflozin → Total daily insulin dose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Empagliflozin reduced Hemoglobin A1C by -0.18%, indicating improved glycemic control.
- Fasting blood sugar levels decreased by -2.60 mg/dL, supporting the efficacy of empagliflozin.
- Total daily insulin doses were reduced by -7.6 units, suggesting less insulin dependency.
A quién se aplica
- Adults with type 1 diabetes
- Patients currently using insulin therapy
Tener en Cuenta
- Results may not apply to younger populations or those not on insulin.
- The study's short duration limits understanding of long-term effects.
- Further research is needed to confirm findings across diverse populations.
Entre Líneas
- Limited generalizability due to specific population characteristics
- Short duration of the study may not capture long-term effects
- Potential for unmeasured confounders affecting outcomes
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Body Mass Index, SGLT2 Inhibitors and Fasting Glucose.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
View evidenceMedications
SGLT2 Inhibitors → Fasting Glucose
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
2 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
2 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
2 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Empagliflozin and BMI
Intervention: EmpagliflozinOutcome: BMI
2 results
All studies on Empagliflozin and Fasting blood sugar (FBS)
Intervention: EmpagliflozinOutcome: Fasting blood sugar (FBS)
2 results
All studies on Empagliflozin
Intervention: Empagliflozin
2 results
All studies measuring BMI
Outcome: BMI
2 results
All studies measuring Fasting blood sugar (FBS)
Outcome: Fasting blood sugar (FBS)
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SGLT2 Inhibitors improve fasting glucose?
Strong Evidence
SGLT2 Inhibitors may improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Fasting blood sugar (FBS)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors affect body mass index?
Strong Evidence
SGLT2 Inhibitors appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve postprandial and ogtt glucose?
Strong Evidence
SGLT2 Inhibitors may improve Postprandial and OGTT Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Glucose iAUC (OGTT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve insulin resistance?
Moderate Evidence
SGLT2 Inhibitors may improve Insulin Resistance.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Total daily insulin dose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Empagliflozin improves heart function in type 2 diabetes patientsEmpagliflozin improves glycemic control in type 2 diabetes patientsEmpagliflozin may reduce kidney disease biomarkers but shows mixed effects on albumin in early diabetesEmpagliflozin reduces liver fat in diabetes patientsEmpagliflozin improves glycemic control in HNF1A-MODY
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.